AppTec and Boehringer Ingelheim's first year of partnering is providing enhanced capabilities and a smooth transition to large-scale manufacturing for clients, according to the companies. Last spring, AppTec announced that Boehringer Ingelheim had become a preferred partner for its commercial cell culture production, including supply of Phase III material and CMC submission to meet specific customer needs. Through this collaboration, AppTec has non-exclusive access to Boehringer’s comprehensive manufacturing technology platform for cell culture products, including its state-of-the-art mammalian high expression system (BI HEX).

For AppTec, the collaboration has resulted in the ability to provide customers with a seamless path to large-scale manufacturing capabilities, according to the company.

“AppTec has been very pleased to be able to include this high-value option in our service offerings for mammalian-cell-based biologics," said Bonnie Baskin, Ph.D., chief executive officer of AppTec. “It further strengthens our ability to provide customers with one-stop solutions that can minimize the time required to move from preclinical to commercial supply of their products.”

“As shown over the past year, AppTec has proved to be an excellent partner for Boehringer Ingelheim, broadening our presence in the U.S. and providing our IP to even more new customers for their time-to-market product development,” commented Prof. Dr. h.c. Rolf G. Werner, senior vice president of the corporate division biopharmaceuticals at Boehringer Ingelheim GmbH.

News from our sister sites